Ascendis Pharma A/S (NASDAQ:ASND) Receives "Outperform" Rating from Wedbush

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s stock had its "outperform" rating restated by Wedbush in a research report issued on Friday, MarketBeat reports. They presently have a $181.00 price target on the biotechnology company's stock. Wedbush's target price indicates a potential upside of 43.07% from the stock's previous close.

A number of other research analysts also recently issued reports on the stock. JPMorgan Chase & Co. dropped their target price on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an "overweight" rating on the stock in a research report on Wednesday, October 23rd. Evercore ISI boosted their target price on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 17th. The Goldman Sachs Group increased their price objective on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a "buy" rating in a research note on Tuesday, September 17th. Wells Fargo & Company upped their price target on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an "overweight" rating in a report on Tuesday, September 17th. Finally, TD Cowen lifted their price objective on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the stock a "buy" rating in a report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $191.77.

Ascendis Pharma A/S Trading Up 1.8 %

Ascendis Pharma A/S stock traded up $2.23 during mid-day trading on Friday, reaching $126.51. The company had a trading volume of 1,448,750 shares, compared to its average volume of 450,130. The business has a fifty day simple moving average of $132.15 and a 200 day simple moving average of $132.80. The company has a market cap of $7.67 billion, a P/E ratio of -13.95 and a beta of 0.66. Ascendis Pharma A/S has a fifty-two week low of $90.13 and a fifty-two week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. Research analysts forecast that Ascendis Pharma A/S will post -7.35 EPS for the current year.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors have recently added to or reduced their stakes in ASND. Price T Rowe Associates Inc. MD grew its holdings in shares of Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company's stock worth $269,374,000 after purchasing an additional 336,976 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Ascendis Pharma A/S by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company's stock worth $1,664,000 after acquiring an additional 4,338 shares in the last quarter. Evolutionary Tree Capital Management LLC grew its stake in Ascendis Pharma A/S by 82.3% in the 2nd quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company's stock worth $3,391,000 after acquiring an additional 11,223 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Ascendis Pharma A/S by 221.0% during the second quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company's stock valued at $833,000 after acquiring an additional 4,205 shares in the last quarter. Finally, Acadian Asset Management LLC raised its stake in shares of Ascendis Pharma A/S by 1,461.1% during the first quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company's stock valued at $37,849,000 after acquiring an additional 234,446 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.